Novel 4-aminoquinoline analogs highly active against the blood and sexual stages of Plasmodium in vivo and in vitro

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4685-4692

  Sáenz, Fabián E ^a,c   Mutka, Tina ^a   Udenze, Kenneth ^a   Oduola, Ayoade M J ^b   Kyle, Dennis E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNICEF   (United States)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; N1 (7 CHLORO QUINOLIN 4 YL) 2 METHYL PROPANE 1,2 DIAMINE; N1 (7 CHLOROQUINOINLIN 4 YL) 2,N2,N2 TRIMETHYLPROPANE 1,2 DIAMINE; TDR 58845; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASEXUAL BLOOD STAGE; CAMBODIA; CLONING; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; GAMETOCYTE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PARASITE ISOLATION; PLASMODIUM; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; THAILAND;

ADMINISTRATION, ORAL; AMINOQUINOLINES; ANIMALS; ANTIMALARIALS; CAMBODIA; CHLOROQUINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; ERYTHROCYTES; HUMANS; INHIBITORY CONCENTRATION 50; LIFE CYCLE STAGES; MALARIA; MICE; MICE, INBRED BALB C; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; SURVIVAL RATE; THAILAND;

EID: 84865440072     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01061-12     Document Type: Article

References (55)

1. Reference deleted.
2. Baird JK, et al. 1991. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. 44:547-552.
3. Batra S, Srivastava P, Roy K, Pandey VC, Bhaduri AP. 2000. A new class of potential chloroquine-resistance reversal agents for Plasmodia: syntheses and biological evaluation of 1-(3′-diethylaminopropyl)-3-(substituted phenylmethylene)pyrrolidines. J. Med. Chem. 43:3428-3433.
4. Bayoumi RA, et al. 1993. Drug response and genetic characterization of Plasmodium falciparum clones recently isolated from a Sudanese village. Trans. R. Soc. Trop. Med. Hyg. 87:454-458.
5. Bitonti AJ, et al. 1988. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science 242:1301-1303. (Pubitemid 19008060)
6. Black F, et al. 1981. Fansidar resistant falciparum malaria acquired in South East Asia. Trans. R. Soc. Trop. Med. Hyg. 75:715-716. (Pubitemid 12174773)
7. Buckling A, Ranford-Cartwright LC, Miles A, Read AF. 1999. Chloroquine increases Plasmodium falciparum gametocytogenesis in vitro. Parasitology 118(Pt 4):339-346. (Pubitemid 29186944)
8. Campbell CC, Chin W, Collins WE, Teutsch SM, Moss DM. 1979. Chloroquine-resistant Plasmodium falciparum from East Africa: cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist. Lancet ii:1151-1154. (Pubitemid 10208358)
9. Collignon P. 1991. Chloroquine resistance in Plasmodium vivax. J. Infect. Dis. 164:222-223.
10. De D, Krogstad FM, Cogswell FB, Krogstad DJ. 1996. Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 55:579-583. (Pubitemid 27110989)
11. Dondorp AM, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
12. Fidock DA. 2010. Drug discovery: priming the antimalarial pipeline. Nature 465:297-298.
13. Fidock DA, et al. 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6:861-871.
14. Fitch CD. 2004. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 74:1957-1972. (Pubitemid 38210349)
15. Ginsburg H, Stein WD. 2005. How many functional transport pathways does Plasmodium falciparum induce in the membrane of its host erythrocyte? Trends Parasitol. 21:118-121. (Pubitemid 40269775)
16. Greenwood BM, et al. 2008. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest. 118:1266-1276. (Pubitemid 351500419)
17. Hastings IM. 2004. The origins of antimalarial drug resistance. Trends Parasitol. 20:512-518. (Pubitemid 39313089)
18. Hastings MD, et al. 2004. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J. Infect. Dis. 189:744-750. (Pubitemid 38270930)
19. Hocart SJ, et al. 2011. 4-Aminoquinolines active against chloroquine-resistant Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses. Antimicrob. Agents Chemother. 55:2233-2244.
20. Hofheinz W, Jaquet C, Jolidon S. 1995. Aminochinoline derivatives useful in the treatment of malaria. European patent EP0656353.
21. Hwang JY, et al. 2011. Synthesis and evaluation of 7-substituted 4-aminoquinoline analogues for antimalarial activity. J. Med. Chem. 54:7084- 7093.
22. Ifediba T, Vanderberg JP. 1981. Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature 294:364-366. (Pubitemid 12202857)
23. Ishih A, Suzuki T, Muregi FW, Matsui K, Terada M. 2006. Chloroquine efficacy in Plasmodium berghei NK65-infected ICR mice, with reference to the influence of initial parasite load and starting day of drug administration on the outcome of treatment. Southeast Asian J. Trop. Med. Public Health 37:13-17. (Pubitemid 43799603)
24. Iwaniuk DP, et al. 2009. Synthesis and antimalarial activity of new chloroquine analogues carrying a multifunctional linear side chain. Bioorg. Med. Chem. 17:6560-6566.
25. Kappe SH, Vaughan AM, Boddey JA, Cowman AF. 2010. That was then but this is now: malaria research in the time of an eradication agenda. Science 328:862-866.
26. Krogstad DJ, et al. 1987. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 238:1283-1285.
27. Kyle DE, Milhous WK, Rossan RN. 1993. Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys. Am. J. Trop. Med. Hyg. 48:126-133. (Pubitemid 23072573)
28. Kyle DE, Oduola AM, Martin SK, Milhous WK. 1990. Plasmodium falciparum: modulation by calcium antagonists of resistance to chloroquine, desethylchloroquine, quinine, and quinidine in vitro. Trans. R. Soc. Trop. Med. Hyg. 84:474-478. (Pubitemid 20266954)
29. Madrid PB, Liou AP, DeRisi JL, Guy RK. 2006. Incorporation of an intramolecular hydrogen-bonding motif in the side chain of 4-aminoquinolines enhances activity against drug-resistant P. falciparum. J. Med. Chem. 49:4535-4543. (Pubitemid 44162680)
30. Madrid PB, et al. 2005. Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities. Bioorg. Med. Chem. Lett. 15:1015-1018. (Pubitemid 40458640)
31. Martin SK, Oduola AM, Milhous WK. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899-901. (Pubitemid 17019130)
32. Millet J, et al. 2004. Polymorphism in Plasmodium falciparum drug transporter proteins and reversal of in vitro chloroquine resistance by a 9,10-dihydroethanoanthracene derivative. Antimicrob. Agents Chemother. 48:4869-4872. (Pubitemid 39577696)
33. Murray CJ, et al. 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413-431.
34. Mzayek F, et al. 2007. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin. Trials 2:e6. doi:10.1371/journal.pctr.0020006.
35. Oduola AM, et al. 1998. In vitro and in vivo reversal of chloroquine resistance in Plasmodium falciparum with promethazine. Am. J. Trop. Med. Hyg. 58:625-629. (Pubitemid 28237262)
36. Omodeo-Sale F, et al. 2009. Novel antimalarial aminoquinolines: heme binding and effects on normal or Plasmodium falciparum-parasitized human erythrocytes. Antimicrob. Agents Chemother. 53:4339-4344.
37. Pagola S, Stephens PW, Bohle DS, Kosar AD, Madsen SK. 2000. The structure of malaria pigment beta-haematin. Nature 404:307-310.
38. Peters W. 1975. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann. Trop. Med. Parasitol. 69:155-171.
39. Reference deleted.
40. Reference deleted.
41. Ponnudurai T, Meuwissen JH, Leeuwenberg AD, Verhave JP, Lensen AH. 1982. The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes. Trans. R. Soc. Trop. Med. Hyg. 76:242-250.
42. Pradines B, Pages JM, Barbe J. 2005. Chemosensitizers in drug transport mechanisms involved in protozoan resistance. Curr. Drug Targets Infect. Disord. 5:411-431. (Pubitemid 43008514)
43. Price RN, et al. 2007. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 77:79-87.
44. Ray S, et al. 2010. Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. J. Med. Chem. 53:3685-3695.
45. Ridley RG, et al. 1996. 4-Aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum. Antimicrob. Agents Chemother. 40:1846-1854. (Pubitemid 26277804)
46. Rieckmann KH, Davis DR, Hutton DC. 1989. Plasmodium vivax resistance to chloroquine? Lancet ii:1183-1184. (Pubitemid 19275451)
47. Saenz FE, Balu B, Smith J, Mendonca SR, Adams JH. 2008. The transmembrane isoform of Plasmodium falciparum MAEBL is essential for the invasion of Anopheles salivary glands. PLoS One 3:e2287. doi: 10.1371/journal.pone.0002287.
48. Smalley ME. 1977. Plasmodium falciparum gametocytes: the effect of chloroquine on their development. Trans. R. Soc. Trop. Med. Hyg. 71: 526-529.
49. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48:1803-1806. (Pubitemid 38544392)
50. Thompson PE, Bayles A, Olszewski B, Waitz JA. 1965. Quinine-resistant Plasmodium berghei in mice. Science 148:1240-1241.
51. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
52. van Schalkwyk DA, Egan TJ. 2006. Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug Resist. Updat. 9:211-226. (Pubitemid 44781212)
53. Warhurst DC, Hall AP, Tjokrosonto S. 1985. RI quinine-Fansidar resistant falciparum malaria from Malawi. Lancet ii:330. (Pubitemid 15045155)
54. Wellems TE, Plowe CV. 2001. Chloroquine-resistant malaria. J. Infect. Dis. 184:770-776. (Pubitemid 32826429)
55. Whitty CJ, Chandler C, Ansah E, Leslie T, Staedke SG. 2008. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar. J. 7(Suppl 1):S7. doi:10.1186/1475-2875-7-S1-S7.